|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited tumor samples versus normal samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
| |
|
Editing gene: ALOX5 (CAeditome ID:240) |
Gene summary for ALOX5 |
 Gene summary |
| Gene information | Gene symbol | ALOX5 | Gene ID | 240 |
| Gene name | arachidonate 5-lipoxygenase | |
| Synonyms | 5-LO|5-LOX|5LPG|LOG5 | |
| Cytomap | 10q11.21 | |
| Type of gene | protein-coding | |
| Description | polyunsaturated fatty acid 5-lipoxygenaseLOX-5arachidonic acid 5-lipoxygenaseleukotriene A4 synthase | |
| Modification date | 20210518 | |
| UniProtAcc | P09917 | |
| Context |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 19022417 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 21233389 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 22516296 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 23246375 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 24282679 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 24893149 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 8615788 |
| ALOX5 | GO:0004051 | Polyunsaturated fatty acid 5-lipoxygenase | 8631361 |
| ALOX5 | GO:0005506 | Polyunsaturated fatty acid 5-lipoxygenase | 21233389 |
| ALOX5 | GO:0019370 | Polyunsaturated fatty acid 5-lipoxygenase | 21233389 |
| ALOX5 | GO:0019370 | Polyunsaturated fatty acid 5-lipoxygenase | 24893149 |
| ALOX5 | GO:0050728 | Polyunsaturated fatty acid 5-lipoxygenase | 21206090 |
| ALOX5 | GO:1901753 | Polyunsaturated fatty acid 5-lipoxygenase | 24282679 |
| ALOX5 | GO:0005635 | Polyunsaturated fatty acid 5-lipoxygenase | 19233132 |
| ALOX5 | GO:0005641 | Polyunsaturated fatty acid 5-lipoxygenase | 8245774 |
| ALOX5 | GO:0005654 | Polyunsaturated fatty acid 5-lipoxygenase | 0000052 |
| ALOX5 | GO:0005829 | Polyunsaturated fatty acid 5-lipoxygenase | 19233132 |
| ALOX5 | GO:0016363 | Polyunsaturated fatty acid 5-lipoxygenase | 19233132 |
| ALOX5 | GO:0031965 | Polyunsaturated fatty acid 5-lipoxygenase | 8245774 |
| ALOX5 | GO:0048471 | Polyunsaturated fatty acid 5-lipoxygenase | 19022417 |
Top |
RNA A-to-I events for ALOX5 |
| RNA A-to-I editing events across TCGA 33 cancers data sets based on Ensembl gene isoform structure. |
 |
| RNA editing frequencies across 33 cancers of gene: ENSG00000012779.9 |
| RNA A-to-I editing events in Cancer. |
| CAediting_746759(45386180, +), CAediting_746760(45386415, +), CAediting_746761(45417098, +), CAediting_746762(45417101, +), CAediting_746763(45417168, +), CAediting_746764(45429947, +), CAediting_746765(45430512, +), CAediting_746766(45430518, +), CAediting_746767(45430522, +), CAediting_746768(45431612, +), CAediting_746769(45431621, +), CAediting_746770(45431672, +), CAediting_746771(45431673, +), CAediting_746772(45431677, +), CAediting_746773(45431690, +), CAediting_746774(45431712, +), CAediting_746775(45432217, +), CAediting_746776(45432221, +), CAediting_746777(45432239, +), CAediting_746778(45432240, +), CAediting_746779(45432245, +), CAediting_746780(45432246, +), CAediting_746781(45432253, +), CAediting_746782(45432280, +), CAediting_746783(45432285, +), CAediting_746784(45432288, +), CAediting_746785(45432339, +), CAediting_746786(45432340, +), CAediting_746787(45433021, +), CAediting_746788(45433025, +), CAediting_746789(45433031, +), CAediting_746790(45433052, +), |
Top |
RNA editing positional annotations for ALOX5 using Annovar |
| Protein coding RNA editing(s). |
| CAeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| Gene structure information of RNA editing(s). |
| CAeditome ID | Position | Variant type |
| CAediting_746759 | chr10_45386180_+ | intronic |
| CAediting_746760 | chr10_45386415_+ | intronic |
| CAediting_746761 | chr10_45417098_+ | intronic |
| CAediting_746762 | chr10_45417101_+ | intronic |
| CAediting_746763 | chr10_45417168_+ | intronic |
| CAediting_746764 | chr10_45429947_+ | intronic |
| CAediting_746765 | chr10_45430512_+ | intronic |
| CAediting_746766 | chr10_45430518_+ | intronic |
| CAediting_746767 | chr10_45430522_+ | intronic |
| CAediting_746768 | chr10_45431612_+ | intronic |
| CAediting_746769 | chr10_45431621_+ | intronic |
| CAediting_746770 | chr10_45431672_+ | intronic |
| CAediting_746771 | chr10_45431673_+ | intronic |
| CAediting_746772 | chr10_45431677_+ | intronic |
| CAediting_746773 | chr10_45431690_+ | intronic |
| CAediting_746774 | chr10_45431712_+ | intronic |
| CAediting_746775 | chr10_45432217_+ | intronic |
| CAediting_746776 | chr10_45432221_+ | intronic |
| CAediting_746777 | chr10_45432239_+ | intronic |
| CAediting_746778 | chr10_45432240_+ | intronic |
| CAediting_746779 | chr10_45432245_+ | intronic |
| CAediting_746780 | chr10_45432246_+ | intronic |
| CAediting_746781 | chr10_45432253_+ | intronic |
| CAediting_746782 | chr10_45432280_+ | intronic |
| CAediting_746783 | chr10_45432285_+ | intronic |
| CAediting_746784 | chr10_45432288_+ | intronic |
| CAediting_746785 | chr10_45432339_+ | intronic |
| CAediting_746786 | chr10_45432340_+ | intronic |
| CAediting_746787 | chr10_45433021_+ | intronic |
| CAediting_746788 | chr10_45433025_+ | intronic |
| CAediting_746789 | chr10_45433031_+ | intronic |
| CAediting_746790 | chr10_45433052_+ | intronic |
| Repat-regional RNA editing(s). |
| CAeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
| CAediting_746759 | chr10_45386180_+ | SINE | Alu | AluY |
| CAediting_746760 | chr10_45386415_+ | SINE | Alu | AluJr |
| CAediting_746761 | chr10_45417098_+ | LINE | L2 | L2c |
| CAediting_746762 | chr10_45417101_+ | LINE | L2 | L2c |
| CAediting_746764 | chr10_45429947_+ | SINE | MIR | MIR |
| CAediting_746765 | chr10_45430512_+ | SINE | Alu | FAM |
| CAediting_746766 | chr10_45430518_+ | SINE | Alu | FAM |
| CAediting_746767 | chr10_45430522_+ | SINE | Alu | FAM |
| CAediting_746768 | chr10_45431612_+ | SINE | Alu | AluSx3 |
| CAediting_746769 | chr10_45431621_+ | SINE | Alu | AluSx3 |
| CAediting_746770 | chr10_45431672_+ | SINE | Alu | AluSx3 |
| CAediting_746771 | chr10_45431673_+ | SINE | Alu | AluSx3 |
| CAediting_746772 | chr10_45431677_+ | SINE | Alu | AluSx3 |
| CAediting_746773 | chr10_45431690_+ | SINE | Alu | AluSx3 |
| CAediting_746774 | chr10_45431712_+ | SINE | Alu | AluSx3 |
| CAediting_746775 | chr10_45432217_+ | SINE | Alu | AluJr |
| CAediting_746776 | chr10_45432221_+ | SINE | Alu | AluJr |
| CAediting_746777 | chr10_45432239_+ | SINE | Alu | AluJr |
| CAediting_746778 | chr10_45432240_+ | SINE | Alu | AluJr |
| CAediting_746779 | chr10_45432245_+ | SINE | Alu | AluJr |
| CAediting_746780 | chr10_45432246_+ | SINE | Alu | AluJr |
| CAediting_746781 | chr10_45432253_+ | SINE | Alu | AluJr |
| CAediting_746782 | chr10_45432280_+ | SINE | Alu | AluJr |
| CAediting_746783 | chr10_45432285_+ | SINE | Alu | AluJr |
| CAediting_746784 | chr10_45432288_+ | SINE | Alu | AluJr |
| CAediting_746785 | chr10_45432339_+ | SINE | Alu | AluJr |
| CAediting_746786 | chr10_45432340_+ | SINE | Alu | AluJr |
| CAediting_746787 | chr10_45433021_+ | LINE | L1 | L1ME3G |
| CAediting_746788 | chr10_45433025_+ | LINE | L1 | L1ME3G |
| CAediting_746789 | chr10_45433031_+ | LINE | L1 | L1ME3G |
| CAediting_746790 | chr10_45433052_+ | LINE | L1 | L1ME3G |
Top |
RNA A-to-I editing events in the alternative splicing sites for ALOX5 |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | CAeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential percent of spliced in (PSI) between RNA A-to-I edited and non-edited samples for ENSG00000012779.9.ALOX5. |
| Correlation between RNA A-to-I editing and PSI for ENSG00000012779.9.ALOX5. |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for ALOX5 |
| Differential gene expressions between RNA A-to-I edited and non-edited tumor samples. * The grey color means N/A. |
 | |
| Correlation between RNA A-to-I editing and gene expression. |
 | |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
Top |
Protein coding region RNA A-to-I editings for ALOX5 |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
Top |
The effects of the RNA editing to the miRNA binding sites for ALOX5 |
| **If you are searching a miRNA gene with RNA editing events in its seed regions, please see the search pages of miRNA targets to discover the effects of this RNA editing event to miRNA regulations. For more information, please check the files in the Download page. |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_393 | chr1_1167164_+ | ENSG00000012779.9 | ENST00000542434 | hsa-miR-200b-3p | 45445922 | 45445928 | 7mer-m8 | 45445907 | 45445929 | 149 | -15.97 |
| CAediting_980496 | chr14_31014685_- | ENSG00000012779.9 | ENST00000612635 | hsa-miR-624-3p | 45425022 | 45425028 | 7mer-m8 | 45425008 | 45425029 | 148 | -18.33 |
| CAediting_1368054 | chr19_46709310_- | ENSG00000012779.9 | ENST00000542434 | hsa-miR-320e | 45445916 | 45445923 | 8mer-1a | 45445906 | 45445923 | 152 | -19.13 |
| CAediting_1229415 | chr17_67471547_+ | ENSG00000012779.9 | ENST00000612635 | hsa-miR-548aa | 45440489 | 45440495 | 7mer-m8 | 45440473 | 45440496 | 164 | -17.51 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for ALOX5 |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| RNA A-to-I editing in RNA structures for Minimum free energy (MFE). |
| CAeditom_ID | ENST | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
Top |
Relation with ADAR for ALOX5 |
| Correlation between ADAR gene expression and RNA editing frequency |
| Cancer | CAeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
| STAD | CAediting_746780 | chr10_45432246_+ | 0.0491932511802071 | 0.279659057959499 | . | . | . | . |
Top |
Relation with cancer stages for ALOX5 |
| Correlation between Cancer stages and RNA editing frequency |
| Cancer | Stage_type | CAeditomID | position | P-val | Coeff. |
Top |
Relation with survival for ALOX5 |
| Correlation between RNA editing and survival |
| Cancer | CAeditomID | position | KMpvalue | Coxpvalue | CoxHR |
Top |
RelatedDrugs for ALOX5 |
| Approved drugs targeting this gene. (DrugBank Version 5.1.8 2021-01-03) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| ALOX5 | P09917 | DB00233 | Aminosalicylic acid | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved |
| ALOX5 | P09917 | DB00244 | Mesalazine | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved |
| ALOX5 | P09917 | DB00471 | Montelukast | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved |
| ALOX5 | P09917 | DB00795 | Sulfasalazine | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved |
| ALOX5 | P09917 | DB00179 | Masoprocol | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational |
| ALOX5 | P09917 | DB01014 | Balsalazide | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational |
| ALOX5 | P09917 | DB01017 | Minocycline | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational |
| ALOX5 | P09917 | DB11994 | Diacerein | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational |
| ALOX5 | P09917 | DB12010 | Fostamatinib | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational |
| ALOX5 | P09917 | DB00711 | Diethylcarbamazine | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational|vet_approved |
| ALOX5 | P09917 | DB00744 | Zileuton | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|investigational|withdrawn |
| ALOX5 | P09917 | DB00163 | Vitamin E | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|nutraceutical|vet_approved |
| ALOX5 | P09917 | DB14001 | alpha-Tocopherol succinate | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|nutraceutical|vet_approved |
| ALOX5 | P09917 | DB14002 | D-alpha-Tocopherol acetate | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|nutraceutical|vet_approved |
| ALOX5 | P09917 | DB00939 | Meclofenamic acid | Arachidonate 5-lipoxygenase | SmallMoleculeDrug | approved|vet_approved |
Top |
RelatedDiseases for ALOX5 |
| Diseases associated with this gene. (DisGeNet 7.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| ALOX5 | C0007102 | Malignant tumor of colon | 3 | CTD_human |
| ALOX5 | C0009375 | Colonic Neoplasms | 3 | CTD_human |
| ALOX5 | C0023473 | Myeloid Leukemia, Chronic | 2 | CTD_human |
| ALOX5 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| ALOX5 | C0001430 | Adenoma | 1 | CTD_human |
| ALOX5 | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| ALOX5 | C0004153 | Atherosclerosis | 1 | CTD_human |
| ALOX5 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| ALOX5 | C0009319 | Colitis | 1 | CTD_human |
| ALOX5 | C0009376 | Colonic Polyps | 1 | CTD_human |
| ALOX5 | C0011609 | Drug Eruptions | 1 | CTD_human |
| ALOX5 | C0020429 | Hyperalgesia | 1 | CTD_human |
| ALOX5 | C0020542 | Pulmonary Hypertension | 1 | CTD_human |
| ALOX5 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| ALOX5 | C0026766 | Multiple Organ Failure | 1 | CTD_human |
| ALOX5 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| ALOX5 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| ALOX5 | C0027719 | Nephrosclerosis | 1 | CTD_human |
| ALOX5 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ALOX5 | C0035126 | Reperfusion Injury | 1 | CTD_human |
| ALOX5 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| ALOX5 | C0042109 | Urticaria | 1 | CTD_human |
| ALOX5 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| ALOX5 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| ALOX5 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| ALOX5 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| ALOX5 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| ALOX5 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| ALOX5 | C0205646 | Adenoma, Basal Cell | 1 | CTD_human |
| ALOX5 | C0205647 | Follicular adenoma | 1 | CTD_human |
| ALOX5 | C0205648 | Adenoma, Microcystic | 1 | CTD_human |
| ALOX5 | C0205649 | Adenoma, Monomorphic | 1 | CTD_human |
| ALOX5 | C0205650 | Papillary adenoma | 1 | CTD_human |
| ALOX5 | C0205651 | Adenoma, Trabecular | 1 | CTD_human |
| ALOX5 | C0235974 | Pancreatic carcinoma | 1 | CTD_human |
| ALOX5 | C0238281 | Middle Cerebral Artery Syndrome | 1 | CTD_human |
| ALOX5 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| ALOX5 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ALOX5 | C0376618 | Endotoxemia | 1 | CTD_human |
| ALOX5 | C0406537 | Morbilliform Drug Reaction | 1 | CTD_human |
| ALOX5 | C0458247 | Allodynia | 1 | CTD_human |
| ALOX5 | C0740376 | Middle Cerebral Artery Thrombosis | 1 | CTD_human |
| ALOX5 | C0740391 | Middle Cerebral Artery Occlusion | 1 | CTD_human |
| ALOX5 | C0740392 | Infarction, Middle Cerebral Artery | 1 | CTD_human |
| ALOX5 | C0751211 | Hyperalgesia, Primary | 1 | CTD_human |
| ALOX5 | C0751212 | Hyperalgesia, Secondary | 1 | CTD_human |
| ALOX5 | C0751213 | Tactile Allodynia | 1 | CTD_human |
| ALOX5 | C0751214 | Hyperalgesia, Thermal | 1 | CTD_human |
| ALOX5 | C0751845 | Middle Cerebral Artery Embolus | 1 | CTD_human |
| ALOX5 | C0751846 | Left Middle Cerebral Artery Infarction | 1 | CTD_human |
| ALOX5 | C0751847 | Embolic Infarction, Middle Cerebral Artery | 1 | CTD_human |
| ALOX5 | C0751848 | Thrombotic Infarction, Middle Cerebral Artery | 1 | CTD_human |
| ALOX5 | C0751849 | Right Middle Cerebral Artery Infarction | 1 | CTD_human |
| ALOX5 | C0919267 | ovarian neoplasm | 1 | CTD_human |
| ALOX5 | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human |
| ALOX5 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| ALOX5 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| ALOX5 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| ALOX5 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| ALOX5 | C1336708 | Testicular Germ Cell Tumor | 1 | CTD_human |
| ALOX5 | C1563937 | Atherogenesis | 1 | CTD_human |
| ALOX5 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| ALOX5 | C2936719 | Mechanical Allodynia | 1 | CTD_human |
